Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OraSure Sees Profitability In 2002 With OraQuick, UPlink Introductions

This article was originally published in The Gray Sheet

Executive Summary

OraSure Technologies expects FDA approvals of its UPlink drugs-of-abuse test and OraQuick rapid HIV assay to help the firm reach profitability this year and grow revenues 30% over 2001

You may also be interested in...



OraSure UPlink

Point-of-care oral fluid opiate detector test system gains 510(k) clearance on April 5. Development of a five-panel oral fluid assay for cocaine, methamphetamine/amphetamine, PCP and marijuana is ongoing; OraSure plans to submit a 510(k) for the indication by mid-summer ("1The Gray Sheet" Jan. 28, 2002, p. 4)...

Civica Rx Gets $55m Investment

Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.

UsernamePublicRestriction

Register

MT016018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel